Janus Kinase Inhibitors as a Therapeutic Option for Chronic Spontaneous Urticaria Refractory to Antihistamines and Omalizumab: A Case Series

Abstract

Keywords

chronic spontaneous urticaria JAK inhibitors omalizumab

Get full access to this article

View all access options for this article.

References

Zhu

BinJadeed

Gabrielli

, et al. Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience. Clin Exp Dermatol. 2024;49(10):1227-1231. doi:10.1093/ced/llae145

Kocaturk

Saini

Rubeiz

Bernstein

JA.

Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring. J Allergy Clin Immunol Pract. 2022;10(12):3099-3116. doi:10.1016/j.jaip.2022.09.038

Maurer

Casale

Saini

, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184-194. doi:10.1016/j.jaci.2024.01.028

Maurer

Metz

Anderson

, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025;80(8):2178–2186. doi:10.1111/all.16598

Metz

Giménez-Arnau

Hide

, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792